<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251471</url>
  </required_header>
  <id_info>
    <org_study_id>OENB-13903</org_study_id>
    <nct_id>NCT01251471</nct_id>
  </id_info>
  <brief_title>Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response</brief_title>
  <official_title>Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pharmaco-MRI study is to investigate neural correlates of variable&#xD;
      antidepressant treatment response driven by genetic variation in multiple genes involved in&#xD;
      depression.&#xD;
&#xD;
      Thirty Major Depressive Disorder (MDD) patients with a concurrent major depressive episode&#xD;
      will undergo three MRI scanning sessions after escitalopram treatment initiation.&#xD;
      Furthermore, extensive behavioral assessments and measures of potential peripheral markers&#xD;
      such lymphocyte mRNA or pharmacological parameters on platelets or lymphocytes will be&#xD;
      performed.&#xD;
&#xD;
      Imaging measures have been suggested to be superior for drug response assessment as compared&#xD;
      to psychometric scales, which hardly correlate with biological parameters. Since imaging&#xD;
      techniques are too expensive and sophisticated for a broad clinical use, this study will&#xD;
      provide pilot data on potential peripheral biomarkers of neural activation being related to&#xD;
      drug response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this pharmaco-MRI study is to investigate neural correlates of variable&#xD;
      antidepressant treatment response driven by genetic variation in multiple genes involved in&#xD;
      depression.&#xD;
&#xD;
      Thirty Major Depressive Disorder (MDD) patients with a concurrent major depressive episode&#xD;
      will undergo three MRI scanning sessions at baseline, 4 hours and 8 weeks after escitalopram&#xD;
      treatment initiation. During each MRI session, one structural and 3 fMRI scans each engaging&#xD;
      different brain circuitries will be performed. All subjects will undergo extensive behavioral&#xD;
      assessment and will be genotyped. Furthermore, potential peripheral markers such lymphocyte&#xD;
      mRNA or pharmacological parameters on platelets or lymphocytes will be assessed.&#xD;
&#xD;
      The investigators expect that genetic variants which have been associated with variable&#xD;
      response to SSRIs in previous Imaging Genetics studies are modulating neural targets of drug&#xD;
      response. Moreover, peripheral markers are expected to correlate with these brain region&#xD;
      measurements.&#xD;
&#xD;
      Imaging measures have been suggested to be superior for drug response assessment as compared&#xD;
      to psychometric scales, which hardly correlate with biological parameters. Since imaging&#xD;
      techniques are too expensive and sophisticated for a broad clinical use, this study will&#xD;
      provide pilot data on peripheral biomarkers of neural activation being related to drug&#xD;
      response. Furthermore, this study will demonstrate whether and how genotypes impact on the&#xD;
      dynamics of neural drug response in vivo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD signal</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram, p.o., 10 mg/d; optional 20 mg/d after 2 weeks for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10 mg/d; optional 20 mg/d after 2 weeks.</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
    <other_name>Cipralex</other_name>
    <other_name>Seroplex</other_name>
    <other_name>Lexamil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age 18 -45 years&#xD;
&#xD;
          -  Right-handedness&#xD;
&#xD;
          -  DSM-IV diagnosis of a major depressive episode (SCID)&#xD;
&#xD;
          -  a MADRS score ≥20 and ≤ 30&#xD;
&#xD;
          -  ability to be managed as outpatients&#xD;
&#xD;
          -  ability to fulfill the criteria to undergo an MRI scan&#xD;
&#xD;
          -  Caucasian subjects of European ancestry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous or concurrent major medical or neurological illness&#xD;
&#xD;
          -  clinically significant abnormal values in routine laboratory screening or general&#xD;
             physical examination&#xD;
&#xD;
          -  DSM-IV diagnosis of substance dependence within the past year, except for caffeine or&#xD;
             nicotine or current substance abuse&#xD;
&#xD;
          -  DSM-IV diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or an&#xD;
             anxiety disorder as a primary diagnosis&#xD;
&#xD;
          -  the use of any psychotropic drug within the last two months unresponsiveness of a&#xD;
             former major depressive episode to an adequate antidepressive drug dosing of at least&#xD;
             6 weeks duration or any kind of therapy resistance&#xD;
&#xD;
          -  a history of severe drug allergy or hypersensitivity or known hypersensitivity to&#xD;
             escitalopram&#xD;
&#xD;
          -  being acutely suicidal either indicated by a score ≥ 5 on item 10 (suicidal thoughts)&#xD;
             on the MADRS or a score ≥ 4 on the HAM-D 21 (suicidal thoughts) or according to the&#xD;
             investigator´s opinion&#xD;
&#xD;
          -  failures to comply with the study protocol or to follow the instructions of the&#xD;
             investigating team&#xD;
&#xD;
          -  current pregnancy or breast feeding&#xD;
&#xD;
          -  metallic implants or other contraindications to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukas Pezawas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Dept. of Psychiatry and Psychotherapy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna, Dept. of Psychiatry and Psychotherapy</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.meduniwien.ac.at/psychiatrie/</url>
    <description>Dep. Psychiatry and Psychotherapy</description>
  </link>
  <reference>
    <citation>Scharinger C, Rabl U, Sitte HH, Pezawas L. Imaging genetics of mood disorders. Neuroimage. 2010 Nov 15;53(3):810-21. doi: 10.1016/j.neuroimage.2010.02.019. Epub 2010 Feb 13. Review.</citation>
    <PMID>20156570</PMID>
  </reference>
  <reference>
    <citation>Pezawas L, Meyer-Lindenberg A. Imaging genetics: Progressing by leaps and bounds. Neuroimage. 2010 Nov 15;53(3):801-3. doi: 10.1016/j.neuroimage.2010.08.001.</citation>
    <PMID>20816317</PMID>
  </reference>
  <reference>
    <citation>Rabl U, Scharinger C, Müller M, Pezawas L. Imaging genetics: implications for research on variable antidepressant drug response. Expert Rev Clin Pharmacol. 2010 Jul;3(4):471-89. doi: 10.1586/ecp.10.35.</citation>
    <PMID>22111678</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Lukas Pezawas</investigator_full_name>
    <investigator_title>Lukas Pezawas, MD, Medical University of Vienna</investigator_title>
  </responsible_party>
  <keyword>major depressive disorder</keyword>
  <keyword>MDD</keyword>
  <keyword>imaging genetics</keyword>
  <keyword>pharmacoMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

